KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target
effective therapies targeting KRAS have yet to be developed
Lung neoplasms are the leading cause of death by cancer worldwide. Non‑small cell lung cancer (NSCLC) constitutes more than 80% of all lung malignancies and the majority of patients present advanced disease at onset. Although KRAS mutations are the most frequently oncogene aberrations in lung adenocarcinoma patients, effective therapies targeting KRAS have yet to be developed. The role of KRAS in NSCLC remains unclear and its predictive and prognostic impact remains controversial. The study of the underlying biology of KRAS in NSCLC patients could help to determine potential candidates to evaluate novel targeted agents and combinations that may allow a tailored treatment for these patients.
KRAS is one of the most common driver mutations in lung adenocarcinoma, yet durable targeted therapies are lacking. Understanding the biology and clinical implications of KRAS mutations is essential to guide drug development, predict patient outcomes, and ultimately improve survival in a population with limited treatment options.
Evidence level: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Related signals
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT